ASC-1 Rabbit Polyclonal Antibody

Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human ASC . This antibody is tested and proven to work in the following applications:

Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human ASC/TMS1 . This antibody is tested and proven to work in the following applications:

Description: The Anti Mouse asc-type Amino Acid Transporter 1 (Asc-1) Polyclonal Antibody is available in Europe and for worldwide shipping via Gentaur.

Description: Rabbit polyclonal to ASC-1.

Description: Rabbit polyclonal ASC antibody

Description: Rabbit polyclonal ASC antibody

Description: ASC Antibody: Apoptosis is regulated by death domain (DD) and/or caspase recruitment domain (CARD) containing molecules and a caspase family of proteases. CARD containing cell death regulators include RAIDD, RICK, BCL10, Apaf-1, ARC, caspase-9, and caspase-2. A novel CARD domain containing protein was recently identified in human and mouse and designated ASC and TMS1. Ectopic expression of ASC/TMS1 induced apoptosis through activation of caspase-9 and inhibited the survival of human breast cancer cells (3, 4). Overexpression of ASC/TMS1 induced DNA fragmentation. ASC/TMS1 is expressed in a variety of human and mouse tissues.

Description: ASC Antibody: Apoptosis is regulated by death domain (DD) and/or caspase recruitment domain (CARD) containing molecules and a caspase family of proteases. CARD containing cell death regulators include RAIDD, RICK, BCL10, Apaf-1, ARC, caspase-9, and caspase-2. A novel CARD domain containing protein was recently identified in human and mouse and designated ASC and TMS1. Ectopic expression of ASC/TMS1 induced apoptosis through activation of caspase-9 and inhibited the survival of human breast cancer cells (3, 4). Overexpression of ASC/TMS1 induced DNA fragmentation. ASC/TMS1 is expressed in a variety of human and mouse tissues.

Description: ASC is a protein encoded by the PYCARD gene which is approximately 21,6 kDa. ASC is localised to the cytoplasm, endoplasmic reticulum, mitochondrion and nucleus. It is involved in toll-like receptor signalling pathways, CLEC7A (Dectin-1) signalling and the innate immune system. It functions as key mediator in apoptosis and inflammation. It promotes caspase-mediated apoptosis involving predominantly caspase-8 and also caspase-9 in a cell type-specific manner. ASC is widely expressed at low levels in human tissues. Mutations in the PYCARD gene may result in chronic recurrent multifocal osteomyelitis and Cinca syndrome. STJ91730 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of ASC protein.

Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-ASC / TMS1 . This antibody is tested and proven to work in the following applications:

Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PYCARD / ASC (aa182-195). This antibody is tested and proven to work in the following applications:

Description: A polyclonal antibody raised in Goat that recognizes and binds to Human PYCARD / ASC (C-Terminus). This antibody is tested and proven to work in the following applications:

Description: ASC peptide

Description: ASC-J9, is antitumor agent. ASC-J9 suppresses castration-resistant prostate cancer growth via degradation of full-length and splice variant androgen receptors targeting both fAR- and AR3-mediated PCa growth by ASC-J9 may represent the novel therapeutic approach to suppress castration-resistant PCa.

Description: ASC-J9, is antitumor agent. ASC-J9 suppresses castration-resistant prostate cancer growth via degradation of full-length and splice variant androgen receptors targeting both fAR- and AR3-mediated PCa growth by ASC-J9 may represent the novel therapeutic approach to suppress castration-resistant PCa.

Description: ASC-J9, is antitumor agent. ASC-J9 suppresses castration-resistant prostate cancer growth via degradation of full-length and splice variant androgen receptors targeting both fAR- and AR3-mediated PCa growth by ASC-J9 may represent the novel therapeutic approach to suppress castration-resistant PCa.